Cipla licenses Qilu's Keytruda biosimilar for the US
- nuaxia
- 4일 전
- 2분 분량
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda.
Cipla subsidiary Invagen Pharmaceuticals has entered into an exclusive licensing and supply partnership with Qilu, which will remain responsible for development, regulatory registration and product supply.
Cipla USA will commercialise the biosimilar in the United States, positioning the company to participate in the future US market for biosimilar versions of Merck's blockbuster cancer immunotherapy Keytruda.
Field | Content |
Alert Type | Deal |
Companies | Cipla; Invagen Pharmaceuticals; Qilu Pharmaceutical |
Deal Type | Exclusive licensing and supply partnership |
Asset or Company | QL2107 |
Therapy Area(s) | Oncology |
Technology or Modality | Pembrolizumab biosimilar; PD-1 monoclonal antibody |
Deal Value | Financial terms were not disclosed |
Geography | United States |
What Happened | Cipla subsidiary Invagen Pharmaceuticals entered into an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of QL2107, a biosimilar referencing Keytruda, in the United States. |
Why It Matters | The partnership gives Cipla access to a potential US biosimilar of one of the world's leading oncology medicines and expands its biologics commercialisation portfolio. |
Supporting Context | Qilu will remain responsible for development, regulatory registration and supply, while Cipla USA will handle commercialisation in the US. |
Strategic Rationale | The deal combines Qilu's biosimilar development capabilities with Cipla's established US commercial infrastructure. |
Potential Impact | A successfully approved pembrolizumab biosimilar could increase competition and broaden access to PD-1 immunotherapy in the US oncology market. |
Key Takeaway | Cipla has secured exclusive US commercialisation rights to Qilu's Keytruda biosimilar candidate QL2107. |
What to Watch | US regulatory development of QL2107 and the timing of potential entry into the pembrolizumab biosimilar market. |
Primary Source | Cipla |
Relevant Date | 3 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글